Gene-level analysis of rare variants in 363,977 whole exome sequences identifies an association of *GIGYF1* loss of function with type 2 diabetes

4

5 Aimee M. Deaton¹, Margaret M. Parker¹, Lucas D. Ward¹, Alexander O. Flynn-Carroll¹, Lucas BonDurant¹,

- 6 Gregory Hinkle¹, Parsa Akbari², Luca A. Lotta², Regeneron Genetics Center^{2*}, DiscovEHR Collaboration³,
- 7 Aris Baras² and Paul Nioi¹
- 8 ¹Alnylam Pharmaceuticals, Cambridge, MA
- 9 ²Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY
- ³Geisinger Health System, Danville, PA
- 11 * For full author and contribution list see Supplementary Information.

12

13 Abstract

- 14 Sequencing of large cohorts offers an unprecedented opportunity to identify rare genetic variants and to
- 15 find novel contributors to human disease. We used gene-based collapsing tests to identify genes
- associated with glucose, HbA1c and type 2 diabetes (T2D) diagnosis in 363,977 exome-sequenced
- 17 participants in the UK Biobank. We identified associations for variants in GCK, HNF1A and PDX1, which
- are known to be involved in Mendelian forms of diabetes. Notably, we uncovered novel associations for
- 19 GIGYF1, a gene not previously implicated by human genetics, in diabetes. GIGYF1 predicted loss of
- function (pLOF) variants associated with increased levels of glucose (0.77 mmol/L increase, $p = 4.42 \times 10^{-1}$
- ¹²) and HbA1c (4.33 mmol/mol, $p = 1.28 \times 10^{-14}$) as well as T2D diagnosis (OR = 4.15, $p = 6.14 \times 10^{-11}$).
- 22 Multiple rare variants contributed to these associations, including singleton variants. GIGYF1 pLOF also
- associated with decreased cholesterol levels as well as an increased risk of hypothyroidism. The
- association of *GIGYF1* pLOF with T2D diagnosis replicated in an independent cohort from the Geisinger
- 25 Health System. In addition, a common variant association for glucose and T2D was identified at the
- 26 *GIGYF1* locus. Our results highlight the role of GIGYF1 in regulating insulin signaling and protecting from
- 27 diabetes.

28 Author Summary

- 29 Genetic studies focused on high impact variants in protein-coding regions of the genome can provide
- 30 valuable insight into the biology of human disease. As these variants tend to be rare, studying them
- 31 requires large cohort sizes and methods to aggregate variants that are likely to have a similar biological
- 32 impact. We studied how rare genetic variants contribute to type 2 diabetes (T2D) using sequencing data
- from 363,977 participants in the UK Biobank, employing methods to aggregate variants at the level of
- 34 individual genes. As well as identifying genes known to be involved in inherited forms of diabetes, we
- 35 uncovered a novel association for *GIGYF1*. *GIGYF1* loss of function associated with increased risk of T2D
- 36 and increased levels of the diabetes biomarkers glucose and HbA1c. This association was also seen in an
- 37 independent dataset. *GIGYF1* encodes a protein that binds a negative regulator of the insulin receptor
- that has not been well-characterized in the literature. By highlighting the importance of GIGYF1 in
- 39 modulating insulin signaling these results may lead to new therapeutic approaches for diabetes as well
- 40 as a new appreciation for *GIGYF1* loss of function as a genetic risk factor for T2D.

41 Introduction

- 42 Human genetics provides powerful methods for understanding the roles of genes and proteins in
- disease and can lead to new therapeutic hypotheses and drug targets. Genetic evidence based on
- sequence variants within coding regions of the genome is better at predicting the efficacy and safety of
- 45 novel therapeutics than evidence from genome-wide association studies (GWAS), which tend to involve
- 46 common noncoding variants [1-3]. Among coding variants, predicted loss of function (pLOF) variants are
- 47 particularly informative in association studies because they establish a direct causal link between
- 48 reduction in gene function and biological outcomes. Additionally, rare missense variants predicted to be
- 49 deleterious can provide valuable biological insights [4, 5]. However, interrogation of the effects of such
- variants is hampered by the rarity of these variants and the cohort sizes needed to identify associations
- 51 [6]. Exome or whole-genome sequencing of large biobanks coupled with gene-level aggregation of rare
- high impact variants can help to circumvent these challenges [4]. Biobanks offer a considerable
- advantage over case-control cohorts as they contain richer phenotyping data which often includes

- 54 biomarker measurements as well as disease diagnoses. This allows a more complete understanding of
- the biological consequences of damaging variants in particular genes [7, 8].
- 56 Diabetes is a disease that has been extensively studied in traditional array-based GWAS with hundreds
- 57 of associations identified to date [9-12]. Although these studies have given insight into some of the
- 58 biological mechanisms contributing to diabetes, most of the reported associations are with variants in
- 59 non-coding regions, making identification of the causal gene challenging. More recently, exome
- sequencing has been applied to discover protein-coding variants that alter the risk of developing type 2
- diabetes (T2D). Sequencing of 20,791 T2D cases followed by the use of gene-based collapsing tests (to
- 62 aggregate predicted damaging variants) identified associations of *SLC30A8*, *MC4R* and *PAM* with T2D
- 63 diagnosis [5].
- 64 Using 363,977 whole exome sequences from the UK Biobank (UKBB) we performed gene-level collapsing
- tests to examine the association of pLOF and damaging missense variants in ~17,000 genes with
- 66 biomarkers of glycemic control, glucose, and glycated hemoglobin (HbA1c), as well as T2D diagnosis.

67 **Results**

68 Gene-level associations with glucose, HbA1c and T2D

- 69 We used 454,787 whole exome sequences from the UK Biobank (UKBB) to identify rare variants with a
- 70 minor allele frequency (MAF) $\leq 1\%$ likely to have functional impact; pLOF variants (i.e. frameshift, stop
- gain, splice donor or splice acceptor variants) called as high confidence by LOFTEE [13] or missense
- variants predicted to be damaging (Combined Annotation Dependent Depletion [CADD] score \geq 25). We
- raidentified 726,422 rare pLOF variants affecting 16,477 genes, 58.5% of which were singletons (carried by
- a single individual), and 2.14 million damaging missense variants in 17,312 genes, 49.6% of which were
- 75 singletons (Supplementary Table 1).
- 76 Given the large proportion of variants present in just a single individual, we used gene-based collapsing
- tests to look for associations with biomarkers of glycemic control and T2D diagnosis. We used two
- variant aggregation strategies; 1) pLOF variants with MAF \leq 1% and 2) damaging missense variants with
- MAF \leq 1% and performed burden testing in the unrelated White population (n=363,977) adjusting for
- 80 age, sex and genetic ancestry via 12 principal components.
- 81 First, we tested genes for association with glucose and HbA1c levels. We required at least 10 variant
- 82 carriers per gene to have measurements based on an examination of genomic inflation at different
- carrier thresholds (Supplementary Figure 1). Using a p-value threshold adjusted for the number of
- variant sets and phenotypes tested ($p \le 7.82 \times 10^{-7}$), four genes significantly associated with glucose
- 85 levels: *GCK* pLOF ($p = 1.56 \times 10^{-9}$, 1.24 mmol/L increase), *GCK* damaging missense ($p = 6.15 \times 10^{-11}$, 0.61
- 86 mmol/L increase), *GIGYF1* pLOF ($p = 4.42 \times 10^{-12}$, 0.77 mmol/L increase) and *G6PC2* damaging missense
- variants (p = 4.62 x 10⁻⁸³, 0.33 mmol/L decrease) (Figure 1, Table 1). The same variant sets also
- associated with HbA1c levels along with 27 additional sets including *HNF1A* pLOF ($p = 2.14 \times 10^{-7}$, 4.01
- 89 mmol/mol increase), *TNRC6B* pLOF ($p = 2.36 \times 10^{-7}$, 3.94 mmol/mol increase) and *PDX1* damaging
- 90 missense variants ($p = 2.54 \times 10^{-7}$, 0.41 mmol/mol increase) (Figure 1, Table 1).
- 91 We then tested aggregated pLOF and damaging missense variants for association with T2D diagnosis
- 92 (n=24,695 cases). Using a p-value threshold adjusted for the number of variant sets tested ($p \le 1.46 \times 10^{-1}$
- ⁶), 6 variant sets significantly associated with T2D; pLOF variants in *GIGYF1*, *GCK*, *HNF1A* and *TNRC6B*

- 94 and damaging missense variants in GCK and PAM (Figure 2, Table 2). As the time of available follow-up
- 95 differs between England, Scotland, and Wales, we controlled for country of recruitment in the
- 96 regression (see Methods). In addition, we confirmed that significant hits did not associate with country
- 97 of recruitment (all p > 0.035) and that hits remained significant when only data from England were
- 98 considered (Supplementary Table 2).

99 Table 1: Gene-level associations with glucose and HbA1c levels

- 100 Association of pLOF or damaging missense variants (CADD score \geq 25) aggregated per gene with glucose
- and HbA1c levels. The effect is shown in standard deviations (SD) of transformed values as well as in
- 102 International Federation of Clinical Chemistry (IFCC) units. Cl; confidence interval.

gene	Variant set	title	pvalue	Effect (SD)	effect (units)	95% Cl -	95% Cl +	units	n carrier measured
GCK	pLOF	glucose	1.56 x 10 ⁻⁹	1.00	1.24	0.84	1.65	mmol/L	35
GIGYF1	pLOF	glucose	4.42 x 10 ⁻¹²	0.62	0.77	0.55	0.98	mmol/L	121
GCK	missense CADD>25	glucose	6.15 x 10 ⁻¹¹	0.49	0.61	0.42	0.79	mmol/L	173
G6PC2	missense CADD>25	glucose	4.62 x 10 ⁻⁸³	-0.27	-0.33	-0.36	-0.3	mmol/L	5128
GCK	pLOF	HbA1c	2.64 x 10 ⁻¹⁷	1.29	8.75	6.73	10.78	mmol/mol	38
GIGYF1	pLOF	HbA1c	1.28 x 10 ⁻¹⁴	0.64	4.33	3.23	5.43	mmol/mol	129
HNF1A	pLOF	HbA1c	2.14 x 10 ⁻⁷	0.59	4.01	2.50	5.53	mmol/mol	68
TNRC6B	pLOF	HbA1c	2.36 x 10 ⁻⁷	0.58	3.94	2.45	5.43	mmol/mol	70
RHAG	pLOF	HbA1c	3.31 x 10 ⁻³⁴	-0.86	-5.81	-6.75	-4.88	mmol/mol	179
EPB41	pLOF	HbA1c	3.14 x 10 ⁻¹⁷	-0.53	-3.58	-4.41	-2.75	mmol/mol	226
PTPRH	pLOF	HbA1c	4.39 x 10 ⁻¹⁰	0.11	0.74	0.51	0.97	mmol/mol	2924
АРОВ	pLOF	HbA1c	6.94 x 10 ⁻⁸	0.23	1.57	1.00	2.15	mmol/mol	478
PLD1	pLOF	HbA1c	2.99 x 10 ⁻⁷	0.23	1.56	0.96	2.16	mmol/mol	438
EPB42	pLOF	HbA1c	6.11 x 10 ⁻⁷	-0.31	-2.08	-2.90	-1.26	mmol/mol	234
GCK	missense CADD ≥ 25	HbA1c	1.86 x 10 ⁻¹⁷	0.56	3.83	2.94	4.71	mmol/mol	201
G6PC2	missense CADD ≥ 25	HbA1c	6.71 x 10 ⁻⁴⁵	-0.18	-1.21	-1.38	-1.04	mmol/mol	5574
PFAS	missense CADD ≥ 25	HbA1c	2.09 x 10 ⁻⁸	-0.05	-0.32	-0.44	-0.21	mmol/mol	12621
PDX1	missense CADD ≥ 25	HbA1c	2.54 x 10 ⁻⁷	0.06	0.41	0.25	0.56	mmol/mol	6694
PIEZO1	missense CADD ≥ 25	HbA1c	1.0 x 10 ⁻¹³²	-0.15	-1.00	-1.07	-0.92	mmol/mol	26726
AMPD3	missense CADD ≥ 25	HbA1c	7.28 x 10 ⁻³⁴	0.13	0.86	0.72	1.00	mmol/mol	8258
PFKM	missense CADD ≥ 25	HbA1c	2.16 x 10 ⁻²⁸	-0.28	-1.92	-2.26	-1.58	mmol/mol	1353
ANK1	missense CADD ≥ 25	HbA1c	3.12 x 10 ⁻¹⁹	-0.13	-0.87	-1.06	-0.68	mmol/mol	4342
PFKL	missense CADD ≥ 25	HbA1c	2.69 x 10 ⁻¹⁴	0.10	0.68	0.50	0.85	mmol/mol	5245
AXL	missense CADD ≥ 25	HbA1c	4.11 x 10 ⁻¹²	-0.08	-0.54	-0.69	-0.39	mmol/mol	6827
LCAT	missense CADD ≥ 25	HbA1c	1.29 x 10 ⁻¹¹	-0.27	-1.82	-2.34	-1.29	mmol/mol	565

PLA2G12A	missense CADD ≥ 25	HbA1c	5.74 x 10 ⁻¹¹	-0.08	-0.51	-0.67	-0.36	mmol/mol	6761
PLD1	missense CADD ≥ 25	HbA1c	1.51 x 10 ⁻¹⁰	0.08	0.57	0.40	0.75	mmol/mol	5180
APEH	missense CADD ≥ 25	HbA1c	1.86 x 10 ⁻¹⁰	0.29	1.96	1.36	2.57	mmol/mol	429
TNFRSF13B	missense CADD ≥ 25	HbA1c	4.63 x 10 ⁻⁹	-0.08	-0.51	-0.68	-0.34	mmol/mol	5470
BLVRB	missense CADD ≥ 25	HbA1c	2.53 x 10 ⁻⁸	-0.07	-0.48	-0.65	-0.31	mmol/mol	5533
TMC8	missense CADD ≥ 25	HbA1c	3.01 x 10 ⁻⁸	0.11	0.77	0.50	1.05	mmol/mol	2095
HK1	missense CADD ≥ 25	HbA1c	1.08 x 10 ⁻⁷	-0.16	-1.08	-1.48	-0.68	mmol/mol	988
SLC4A1	missense CADD ≥ 25	HbA1c	1.76 x 10 ⁻⁷	-0.15	-1.04	-1.43	-0.65	mmol/mol	1025
TFR2	missense CADD ≥ 25	HbA1c	4.24 x 10 ⁻⁷	-0.12	-0.84	-1.16	-0.51	mmol/mol	1491
CARHSP1	missense CADD ≥ 25	HbA1c	6.78 x 10 ⁻⁷	-0.13	-0.86	-1.20	-0.52	mmol/mol	1360

103

104 Table 2: Gene-level associations with T2D diagnosis

- 105 Association of pLOF or damaging missense variants (CADD score ≥ 25) aggregated per gene with T2D
- 106 diagnosis. OR; odds ratio, CI; confidence interval.

gene	Variant set	title	pvalue	OR	95% CI -	95% CI	N cases	Ν	N carrier	N
						+		carrier	cases	expected
GCK	pLOF	T2D	2.96 x 10 ⁻¹⁵	14.16	7.33	27.34	24695	40	19	2.71
GIGYF1	pLOF	T2D	6.14 x 10 ⁻¹¹	4.15	2.71	6.37	24695	131	29	8.89
HNF1A	pLOF	T2D	1.23 x 10 ⁻⁹	5.27	3.08	9	24695	73	20	4.95
TNRC6B	pLOF	T2D	2.00 x 10 ⁻⁷	4.44	2.53	7.79	24695	71	17	4.82
PAM	missense CADD ≥ 25	T2D	2.26 x 10 ⁻¹²	1.31	1.21	1.41	24695	9357	801	634.85
GCK	missense CADD > 25	T2D	1.70 x 10 ⁻⁸	2.96	2.03	4.32	24695	202	34	13.71

107

108 Identification of genes with a biological role in diabetes

109 Variants in two genes, GCK and GIGYF1, significantly associated with glucose, HbA1c and T2D diagnosis,

strongly suggesting a biological role in diabetes; *GCK* is involved in Mendelian forms of diabetes while

111 GIGYF1 has not previously been implicated by genetics in the disease. Both GCK and GIGYF1 are located

on chromosome 7 but are 56Mb apart, strongly suggesting that these signals are independent; this

- independence was confirmed by conditional analysis (Supplementary Table 3). Two additional variant
- sets, *HNF1A* pLOF and *TNRC6B* pLOF, had genome-wide associations with both T2D diagnosis and HbA1c
- 115 levels while *G6PC2* damaging missense associated with decreased levels of both glucose and HbA1c but
- 116 not T2D diagnosis (Table 3).
- 117 To see which other significant genes were likely to have a role in diabetes we looked at all variant sets
- 118 with a significant glucose, HbA1c, or T2D association and examined whether they had associations with
- additional diabetes traits using a more permissive p-value threshold correcting for the number of variant

- sets tested ($p \le 0.0016$, 32 sets tested). Damaging missense variants in *PDX1* and *PFAS*, which had
- significant associations with HbA1c levels in our primary analysis, associated with T2D diagnosis using
- 122 this threshold (Table 3 and Supplementary Table 4).
- 123 Many HbA1c associations appeared to be secondary to effects on red blood cells. 22 out of 31 variant
- sets associated with HbA1c did not show effects on glucose levels or T2D diagnosis (Supplementary
- 125 Table 4) and were not implicated in Mendelian forms of diabetes. Out of these 22 variant sets, 12 were
- in genes implicated in Mendelian disorders affecting red blood cells (for example *EPB42* and *TFR2*; see
- 127 Supplementary Table 5) and an additional five had highly significant associations with red blood cell
- 128 traits in our data ($p \le 7.82 \times 10^{-7}$; Supplementary Table 6).
- 129 We focused on the variant sets associated with multiple diabetes traits as these are strong candidates
- 130 for regulating glucose homeostasis. The genes fall into three main groups; known MODY (maturity-onset
- diabetes of the young) genes (GCK, HNF1A and PDX1) [14], known genes reported in previous exome-
- 132 wide analyses of glucose levels or T2D (*G6PC2* and *PAM*) [5, 15], and novel genes not previously
- 133 implicated by genetics in diabetes (*GIGYF1*, *TNRC6B* and *PFAS*).
- Because obesity is linked to the development of T2D, we adjusted for body mass index (BMI) in the
- burden tests and found that the association of variants in these genes with diabetes-related traits
- 136 remained significant (Supplementary Tables 7 and 8).
- 137 Associations for rare variants can be susceptible to confounders such as population stratification and
- 138 sample relatedness leading to false positives. Therefore, we used the generalized linear mixed model
- 139 implemented by SAIGE-Gene which accounts for relatedness and adjusts for unbalanced case-control
- ratios [16] to verify association of our variant sets of interest with glucose, HbA1c, and T2D diagnosis.
- 141 SAIGE-Gene was run in the White population including related individuals (n=398,574). Using the p-
- value thresholds previously employed, all associations were statistically significant using this method
- apart from the associations of *TNRC6B* pLOF with HbA1c ($p = 6.85 \times 10^{-6}$) and T2D diagnosis ($p = 4.77 \times 10^{-6}$)
- 144 10⁻⁵) which were less significant (Supplementary Table 9).
- 145 To maximize power to detect associations for rare variants, our original analysis of glucose and HbA1c
- 146 included individuals with a diabetes diagnosis. Associations for all variant sets of interest were at least
- nominally significant when such individuals were excluded from the analysis (Supplementary Table 10).
- 148 For *GIGYF1* pLOF, there was still a substantial effect on glucose (p=2.95 x 10⁻⁸, effect = 0.53 SD) and
- HbA1c ($p=8.29 \times 10^{-7}$, effect = 0.43 SD) levels in carriers without a formal diabetes diagnosis.

150 Table 3: Genes and variant sets associated with multiple diabetes-related traits

151 Variant sets significant for at least one trait in our primary analysis that are also associated with

- additional diabetes traits ($p \le 0.0016$, 32 sets tested). Effect is shown in SD of transformed values or as
- an odds ratio (OR).

gene	Variant set	Pvalue	Effect Pvalue		Effect	Pvalue T2D	OR T2D
		glucose	glucose	HbA1c	Hba1c		
GCK	pLOF	1.56 x 10 ⁻⁹	0.999	2.64 x 10 ⁻¹⁷	1.292	2.96 x 10 ⁻¹⁵	14.16
HNF1A	pLOF	0.01	0.317	2.14 x 10 ⁻⁷	0.592	1.23 x 10 ⁻⁹	5.27
GIGYF1	pLOF	4.42 x 10 ⁻¹²	0.616	1.28 x 10 ⁻¹⁴	0.639	6.14 x 10 ⁻¹¹	4.15
GCK	missense CADD ≥ 25	6.15 x 10 ⁻¹¹	0.487	1.86 x 10 ⁻¹⁷	0.565	1.70 x 10 ⁻⁸	2.96

PAM	missense	0.92	0.001	0.009	0.026	2.26 x 10 ⁻¹²	1.31
	CADD ≥ 25						
TNRC6B	pLOF	4.01 x 10 ⁻⁵	0.507	2.36 x 10 ⁻⁷	0.582	2.00 x 10 ⁻⁷	4.44
PDX1	missense	0.02	0.029	2.54 x 10 ⁻⁷	0.060	3.99 x 10 ⁻⁵	1.21
	CADD ≥ 25						
PFAS	missense	0.32	0.009	2.09 x 10 ⁻⁸	-0.048	4.43 x 10 ⁻⁴	0.88
	CADD ≥ 25						
G6PC2	missense	4.62 x 10 ⁻⁸³	-0.266	6.71 x 10 ⁻⁴⁵	-0.179	0.97	1.00
	CADD ≥ 25						

154

155 GIGYF1 pLOF associations replicate using independent datasets

156 We sought to use independent measurements of glucose and HbA1c to verify the associations of

- 157 interest seen in our primary analysis which used measurements taken as part of the UKBB assessment.
- 158 To do this we extracted lab test values for glucose and HbA1c from primary care data, which is available
- 159 for approximately half of the cohort, taking the mean measurement per individual. In gene-based
- 160 burden tests all variant sets showed a direction of effect consistent with that seen in the primary
- 161 analysis and 10 out of 12 of these were significant when correcting for the number of tests performed (p
- 162 ≤ 0.004). This included the association of *GIGYF1* pLOF with glucose (p=2.10 x 10⁻⁶, effect = 0.65 SD) and
- 163 HbA1c (p=1.19 x 10⁻⁵, effect = 0.74 SD) levels (Supplementary Figure 2 and Supplementary Table 11).
- 164 We then assessed whether rare variants in *GIGYF1* and the other novel genes associated with T2D
- 165 replicated in an independent exome-sequencing cohort. Gene-based tests in European ancestry
- 166 individuals from the Geisinger Health System (GHS; 25,846 T2D cases and 63,749 controls) confirmed
- the association of *GIGYF1* pLOF with T2D (p=0.01, OR=1.8). We did not replicate the association of
- 168 TNRC6B pLOF with T2D. We also tested an expanded PFAS variant set (pLOF + deleterious missense) and
- did not detect an association with T2D (Supplementary Table 12). Notably variant set definitions varied
- somewhat from those used in our primary analysis (see Methods).

171 Multiple variants contribute to associations with diabetes diagnosis and

172 biomarkers

- 173 To examine whether specific variants were driving the associations with diabetes traits we conducted
- 174 "leave-one-out" burden tests. The association of *PAM* missense variants with T2D diagnosis was driven
- entirely by a previously reported variant Ser539Trp (rs78408340; p = 0.43 when Ser539Trp is excluded).
- 176 For all other variant sets, multiple variants contributed to the associations observed (Supplementary
- 177 Figure 3). Notably, when singleton variants were excluded, half of the associations no longer reached
- significance including those for *GCK* pLOF and glucose (p = 0.0015 without singletons versus p = 1.56 x10⁻¹
- ⁹) and *GIGYF1* pLOF and T2D ($p = 2.9 \times 10^{-5}$ without singletons versus $p = 6.14 \times 10^{-11}$) (Supplementary
- 180 Table 13), demonstrating the power of including singletons in gene-based tests.
- 181 For the variants contributing to our novel discovered associations, *GIGYF1* pLOF, *TNRC6B* pLOF and *PFAS*
- damaging missense variants, we examined the quality scores, sequencing depth, transcripts affected
- and presence of contributing variants in gnomAD. We found that for *GIGYF1* and *PFAS* the variants
- 184 contributing most to the associations had good quality scores and depth and were present in the non-
- 185 Finnish European population in gnomAD. In contrast, *TNRC6B* is a highly constrained gene and the most
- 186 common pLOF variant is not present in gnomAD. It is possible pLOF variants for constrained genes may
- 187 not result in true loss of function (see Supplementary Note and Supplementary Figure 4). This

- 188 observation along with the fact that the association of *TNRC6B* pLOF with T2D did not replicate in
- 189 Geisinger Health System leads us to view this association with suspicion.

Replication of published gene-level associations with T2D and associations for T2D drug target genes

- 192 The association between predicted damaging variants in *PAM* and T2D diagnosis was previously
- reported in an exome-sequencing study performed by Flannick and colleagues [5]. We examined
- 194 whether the other two significant genes in the study, *SLC30A8* and *MC4R*, associated with diabetes traits
- in our analysis. Both pLOF and damaging missense variants in *SLC30A8* associated with reduced levels of
- 196 HbA1c and glucose and suggestively associated with decreased incidence of T2D diagnosis
- 197 (Supplementary Table 14). Combining *SLC30A8* pLOF and missense variants resulted in more significant
- associations with glucose ($p = 2.71 \times 10^{-6}$), HbA1c ($p = 8.64 \times 10^{-10}$) and T2D diagnosis (p = 0.005)
- 199 (Supplementary Table 14). There were no *MC4R* high confidence pLOF variants in our dataset and *MC4R*
- 200 predicted damaging missense variants did not associate with diabetes-related traits in our study (all p >
- 201 0.19). We note that the *MC4R* lle269Asn variant driving the association in Flannick and colleagues'
- analysis is absent from our dataset, consistent with the fact that it is absent from European populations
- 203 in gnomAD.
- 204 We also examined whether we detect associations for the 8 genes encoding T2D drug targets (GLP1R,
- 205 IGF1R, PPARG, INSR, SLC5A2, DPP4, KCNJ11, ABCC8). Variant sets in three of these genes, DPP4, GLP1R
- and *KCNJ11* significantly associated with either T2D diagnosis or HbA1c levels (p < 0.003 correcting for
- 207 15 variant sets tested) and an additional 4 genes had a nominally significant association with T2D and/or
- 208 HbA1c (Supplementary Figure 5 and Supplementary Table 15).

209 PheWAS of GIGYF1 pLOF reveals associations with cholesterol levels,

210 hypothyroidism and complications of diabetes

- 211 The most significant novel associations were seen for GIGYF1 pLOF which associated with increased
- 212 glucose and HbA1c levels as well as increased incidence of T2D diagnosis. *GIGYF1* encodes a protein
- named for its binding to GRB10 (GRB10 interacting GYF protein 1), an adapter protein that has been
- shown to bind both the insulin and IGF-1 receptors. The association between *GIGYF1* pLOF and
- increased diabetes risk indicates that *GIGYF1* has a role in regulating insulin signaling and in protecting
- from diabetes. To give additional insight into the biological roles of GIGYF1 we performed a phenome-
- wide association study (PheWAS) testing *GIGYF1* pLOF for association with 142 quantitative traits and
- 218 262 ICD10-coded diagnoses. Based on the number of tests performed, the threshold for significance was
- 219 $p \le 1.22 \times 10^{-4}$ (Figure 4).
- 220 *GIGYF1* pLOF strongly associated with decreased levels of total cholesterol ($p=2.44 \times 10^{-12}$, effect = -0.61
- SD) which was, in large part, driven by LDL cholesterol ($p = 2.40 \times 10^{-10}$, effect = -0.56 SD) although an
- effect on HDL cholesterol was also observed (Table 4). To understand the extent to which this is
- influenced by the use of cholesterol-lowering medication in diabetics, we adjusted for medication use in
- the regression and performed a separate analysis excluding those on cholesterol-lowering medication.
- The association between *GIGYF1* pLOF and LDL cholesterol levels was significant in both analyses
- 226 (Supplementary Table 16). GIGYF1 pLOF also associated with decreased grip strength and decreased
- 227 peak expiratory flow which may reflect changes in body size, muscle mass or general health in carriers
- 228 [17, 18]. Notably, GIGYF1 pLOF also associated with increased levels of the kidney injury biomarker

- 229 cystatin c ($p= 6.65 \times 10^{-6}$, effect = 0.36 SD) and increased diagnosis of urinary system disorders (p = 7.32230 $\times 10^{-5}$, OR = 2.71) which might suggest renal complications of diabetes in carriers (Table 4 and Table 5).
- After diabetes, the most significant disease association of *GIGYF1* pLOF was with increased risk of
- hypothyroidism ($p = 1.25 \times 10^{-9}$, OR = 4.53). 21 out of the 131 *GIGYF1* pLOF carriers had a diagnosis of
- unspecified hypothyroidism and 7 of these also had a diagnosis of T2D. Given the autoimmune
- component in hypothyroidism and type 1 diabetes (T1D), we examined the association of *GIGYF1* pLOF
- with T1D diagnoses but did not detect a significant association (p = 0.1). *GIGYF1* pLOF significantly
- associated with increased risk of syncope and collapse ($p = 1.92 \times 10^{-6}$, OR = 3.75), possibly reflecting
- complications of diabetes or thyroid disorders (Table 5).
- 238 Other phenome-wide significant associations with quantitative traits included waist circumference, total
- protein and mean corpuscular hemoglobin as well increased time to complete a cognitive test (Table 4).
- 240 To ensure that the association of *GIGYF1* pLOF with HbA1c was independent of effects on hemoglobin
- 241 we adjusted for mean corpuscular hemoglobin level and verified that the association remained highly
- significant ($p = 4.10 \times 10^{-12}$). *GIGYF1* pLOF also associated with increased diagnosis of emphysema and
- 243 anemia (Table 5).

Table 4: PheWAS of *GIGYF1* pLOF – quantitative traits

- Showing significant results for burden tests on quantitative traits ($p \le 1.22 \times 10^{-4}$). Effect is shown in
- standard deviations (SD) of transformed values. RH; right hand, LH; left hand.

gene	variant	title	pvalue	Effect	95% CI -	95% CI +	n carrier
	set			(SD)			measured
GIGYF1	pLOF	HbA1c	1.28×10^{-14}	0.64	0.48	0.80	129
GIGYF1	pLOF	cholesterol	2.44 x 10 ⁻¹²	-0.61	-0.78	-0.44	128
GIGYF1	pLOF	glucose	4.42 x 10 ⁻¹²	0.62	0.44	0.79	121
GIGYF1	pLOF	LDL cholesterol	2.40 x 10 ⁻¹⁰	-0.56	-0.73	-0.38	128
GIGYF1	pLOF	apolipoprotein b	2.52 x 10 ⁻¹⁰	-0.56	-0.73	-0.39	127
GIGYF1	pLOF	LH grip strength	5.11 x 10 ⁻¹⁰	-0.37	-0.49	-0.25	131
GIGYF1	pLOF	RH grip strength	1.01 x 10 ⁻⁸	-0.34	-0.46	-0.23	131
GIGYF1	pLOF	peak expiratory flow	5.73 x 10 ⁻⁸	-0.41	-0.56	-0.26	114
GIGYF1	pLOF	cystatin c	6.65 x 10 ⁻⁶	0.36	0.20	0.51	128
GIGYF1	pLOF	mean corpuscular	6.80 x 10 ⁻⁶	-0.38	-0.55	-0.22	128
		hemoglobin	-				
GIGYF1	pLOF	HDL cholesterol	1.53 x 10 ⁻⁵	-0.35	-0.52	-0.19	121
GIGYF1	pLOF	time to complete round	1.67 x 10 ⁻⁵	0.35	0.19	0.51	129
		(cognitive test)					
GIGYF1	pLOF	waist circumference	3.98 x 10 ⁻⁵	0.32	0.16	0.47	130
GIGYF1	pLOF	total protein	6.45 x 10 ⁻⁵	-0.36	-0.53	-0.18	121
GIGYF1	pLOF	apolipoprotein a	6.88 x 10 ⁻⁵	-0.33	-0.49	-0.17	121

247

248 Table 5: PheWAS of GIGYF1 pLOF – ICD10-coded diagnoses

Showing significant results for burden tests on ICD10 coded diagnoses with \geq 500 cases and \geq 1 expected

250 case carrier ($p \le 1.22 \times 10^{-4}$). OR; odds ratio.

gene	Variant	title	pvalue	OR	95% CI	95% CI	N cases	N carrier	Ν
	set				-	+		cases	expected
GIGYF1	pLOF	E11 T2D	6.14 x 10 ⁻¹¹	4.15	2.71	6.37	24695	29	8.89
GIGYF1	pLOF	E03 other hypothyroidism	1.25 x 10 ⁻⁹	4.53	2.78	7.38	19417	21	6.99
GIGYF1	pLOF	R55 syncope and collapse	1.90 x 10 ⁻⁶	3.75	2.18	6.47	12706	15	4.57
GIGYF1	pLOF	D50 iron deficiency anemia	8.52 x 10 ⁻⁶	3.56	2.04	6.23	12886	14	4.64
GIGYF1	pLOF	J43 emphysema	1.99 x 10 ⁻⁵	6.13	2.67	14.10	3015	6	1.09
GIGYF1	pLOF	N39 other disorders of urinary system	7.32 x 10 ⁻⁵	2.71	1.66	4.45	24581	19	8.85

251

252 Common variants at *GIGYF1* associate with glucose, T2D and *GIGYF1*

253 expression

254 Replication is a challenge for rare variant association studies. Despite the rarity of *GIGYF1* pLOF variants,

we replicated the T2D association in an independent cohort. In addition, we looked for more common

- variants that could further implicate the *GIGYF1* locus in diabetes. We tested array genotyped and
- imputed variants at the *GIGYF1* locus for association with glucose levels in 294,042 unrelated White
- individuals with measurements available. We found a cluster of variants in a linkage disequilibrium block
- covering *GIGYF1* and *EPO* significantly associating with glucose levels (Figure 4). This signal is
- represented by rs221783, an intergenic variant whose minor T allele associated with decreased glucose
- 261 (p = 1.8×10^{-11} , effect = -0.03 SD,) and HbA1c (p = 3.6×10^{-7} , effect = -0.02 SD,) levels as well as increased
- 262 cholesterol (p = 7.0×10^{-12} , effect = 0.03 SD,). This variant also associated with a decreased risk of T2D (p
- 263 = 0.005, OR = 0.96) and hypothyroidism (p = 6.95×10^{-7} , OR=0.92) (Table 6). rs221783 is the best eQTL
- 264 ($R^2 > 0.8$) for *GIGYF1* in several tissues including pancreas, adipose and thyroid [19] (Supplementary
- Table 17). In all tissues, the T allele associating with decreased glucose and decreased T2D risk
- associated with increased *GIGYF1* expression. Conditional analysis showed that the glucose and HbA1c
- associations of *GIGYF1* pLOF and rs221783 are independent of each other (Supplementary Table 18).
- The association of rs221783 with glucose levels replicated in Biobank Japan ($p = 1.7 \times 10^{-4}$, effect = -0.05
- 269 SD for T allele) [20] whilst in FinnGen, rs221783 showed a nominal association with T2D diagnosis (p =
- 270 0.02, OR = 0.96 for T allele) (Supplementary Table 19). The association with thyroid disease has been
- 271 replicated elsewhere [21].
- 272 The independent glucose and T2D associations at the *GIGYF1* locus and their replication in other
- 273 datasets further support the hypothesis that decreasing GIGYF1 predisposes to diabetes while increasing
- 274 GIGYF1 levels may protect from diabetes.
- Table 6: Common variant associations at the *GIGYF1* locus
- Associations for the array-typed variant rs221783. For quantitative traits the effect is shown in standard
- 277 deviations (beta) and for diagnoses as an odds ratio (OR). MAF; minor allele frequency.

phenotype	chrom	Pos	Ref	Alt	rsid	MAF	pvalue	Effect	95% CI	95% CI
		(hg19/hg38)	(effect					(beta/OR)	-	+
			allele)							

glucose	7	100292914/	Т	С	rs221783	11%	1.82x10 ⁻¹¹	-0.03	-0.03	-0.02
HbA1c	7	100292914/ 100695291	Т	С	rs221783	11%	3.58x10 ⁻⁷	-0.02	-0.03	-0.01
Cholesterol	7	100292914/ 100695291	Т	С	rs221783	11%	7.00x10 ⁻¹²	0.03	0.02	0.03
LDL	7	100292914/ 100695291	Т	С	rs221783	11%	6.25x10 ⁻¹⁰	0.02	0.02	0.03
T2D	7	100292914/ 100695291	Т	С	rs221783	11%	0.005	0.96	0.93	0.99
Hypothyroidism	7	100292914/ 100695291	Т	С	rs221783	11%	6.95x10 ⁻⁷	0.92	0.88	0.95

278

279 Identification of causal genes at GWAS loci

280 Given the fact that the *GIGYF1* locus harbors both rare and common variants associated with T2D we

examined whether our study points to the causal gene at additional GWAS loci. For 558 variants

associated with T2D in a recent study by Vujkovic and colleagues [9] we tested whether either of the

- two closest genes associated with T2D or HbA1c levels in our study. Just nine genes close to these 558
- variants significantly associated with T2D or HbA1c ($p \le 2.41 \times 10^{-5}$ adjusting for 2071 variant sets tested)
- 285 ANK1, GCK, HNF1A, TNRC6B, SLC30A8, NF1, IRS2, CFTR and HNF4A (Supplementary Figure 6 and
- 286 Supplementary Table 20). Most of these genes are already known to be causal for T2D including GCK,
- 287 HNF1A, SLC30A8, IRS2 and HNF4A. Given that there is a common variant association with T2D at
- 288 *TNRC6B* but conflicting results for *TNRC6B* pLOF in UKBB and GHS, further study of this locus may be warranted.
- 205 Wallantea.

290 Discussion

291 Our results highlight the power of whole exome sequencing to make novel discoveries relevant to

- 292 human disease and to detect known associations of Mendelian disease genes. Gene-level aggregation
- and burden testing of rare pLOF and predicted damaging missense variants identified genes associating
- with diabetes and biomarkers of glycemic control. These included several genes not previously
- implicated in diabetes, *GIGYF1*, *TNRC6B* and *PFAS*, as well as *GCK*, *HNF1A* and *PDX1*, known MODY genes
- [14, 22-24]. We also identified *PAM* and *G6PC2*, genes highlighted by other rare-variant studies of T2D
- and glucose levels [5, 15]. Gene-level tests were needed to detect the majority of these associations
 owing to the rarity of the variants. For example, out of 363,977 individuals, just 40 carried a pLOF variant
- in *GCK* and 131 carried a pLOF variant in *GIGYF1*. In general, singleton variants contributed a large part
- of the signal arguing strongly, as others have done [4], for including such variants in gene-based
- 301 collapsing tests.
 - 302 Test statistic inflation can be a challenge when testing rare variants as statistical assumptions break
 - down when the number of carriers expected to have the disease of interest is low [4, 25]. To avoid false
 - positives in our analysis of diabetes, we initially examined associations with glucose and HbA1c because
 - 305 quantitative traits are less susceptible to inflation. All of the variant sets that associated with T2D also
 - affected HbA1c and/or glucose levels giving us confidence in these associations. In addition, T2D
 - 307 associations for all genes, apart from *TNRC6B*, were significant ($p \le 1.46 \ge 10^{-6}$) using the linear mixed
 - 308 model implemented by SAIGE-Gene which can be more robust when dealing with low numbers of
 - 309 variant carriers [16]. We also verified the majority of our associations with glucose and HbA1c levels,

310 including those for *GIGYF1* pLOF, using independent measurements from primary care data. Additional

- 311 confidence in our results comes from the fact that we identified genes known to be involved in
- 312 Mendelian forms of diabetes and previously reported genes. In addition, a targeted analysis of the genes
- encoding T2D drug targets revealed HbA1c and/or T2D associations for variants in several of these
- genes. The lack of association for variants in some of these drug target genes may partly be due to a lack
- of statistical power. Several of these genes are constrained for pLOF variation and/or have small
- numbers of pLOF carriers in UKBB (for example, *PPARG* has just 16 pLOF carriers). However, for some of
- these genes such as *SLC5A2* (encoding SGLT2) we do not detect associations with diabetes traits despite
- 318 good numbers of variant carriers.
- 319 We uncovered novel associations with T2D and biomarkers of glycemic control for aggregated variants
- in *GIGYF1*, *TNRC6B* and *PFAS* and attempted replication of these associations in exome-sequenced
- individuals from GHS. The association of *GIGYF1* pLOF with T2D replicated in this cohort but we did not
- 322 replicate associations for TNRC6B and PFAS variants. There are differences between these two cohorts;
- 323 UKBB is a population-based cohort with T2D diagnoses obtained from inpatient records while GHS is a
- health system-based cohort and includes both inpatient and outpatient diagnoses. There is a larger
- effect size for *GIGYF1* pLOF in UKBB compared to GHS which may be due to these differences in
- 326 ascertainment. Differences in the definition of the variant sets tested especially for *PFAS* (see Methods)
- 327 or the frequency of the relevant variants (for example, the frequency of *TNR6CB* pLOF is 0.01% in UKBB
- but 0.16% in GHS) may have contributed to the failure to replicate the *TNRC6B* and *PFAS* associations.
- 329 Alternatively, this may suggest that the *TNRC6B* and *PFAS* associations are false positives.
- We focused our analysis on understanding the consequences of *GIGYF1* pLOF as it strongly associated with glucose, HbA1c and T2D and the T2D association replicated in GHS. *GIGYF1* encodes a protein that
- was initially identified for its binding to the adapter protein GRB10 which negatively regulates both the
- insulin and IGF-1 receptors [26]. Transfection of cells with GRB10-binding fragments of GIGYF1 lead to
- 334 greater activation of both the insulin and IGF-1 receptors [27]. This supports a hypothesis whereby
- 335 GIGYF1 enhances insulin signaling by reducing the negative regulation of the insulin receptor by GRB10.
- 336 When GIGYF1 is reduced, as is the case in individuals carrying pLOF variants, GRB10 presumably inhibits
- insulin signaling to a greater degree thereby reducing the action of insulin in its target tissues and
- 338 leading to increased risk of T2D. However, the exact mechanistic details of these interactions remain to
- be determined. *GRB10* variants have also been reported to associate with T2D and glycemic traits
- although interpretation of these results is complicated by imprinting [28, 29]. *GIGYF1* is broadly
- 341 expressed with high levels observed in endocrine tissues, pancreas and brain [19, 30]. GIGYF1 and the
- 342 related protein GIGYF2 have also been implicated in translational repression [31] and translation-
- coupled mRNA decay [32] suggesting biological roles beyond regulation of insulin and IGF-1 receptor
- 344 signaling.
- 345 PheWAS of *GIGYF1* pLOF revealed a strong association with decreased cholesterol levels reflecting
- 346 altered energy homeostasis in carriers. An inverse relationship between glucose and cholesterol levels
- has been observed for variants in other genes [33]. We also observed several associations that could
- 348 reflect complications of diabetes in *GIGYF1* pLOF carriers including increased cystatin c levels and
- increased diagnosis of urinary disorders, suggesting renal complications, as well as syncope and collapse
- which may be a side-effect of hyperglycemia and/or hypoglycemia in diabetics. Other associations may
- reflect poor health in carriers including decreased grip strength and decreased peak expiratory flow.
- 352 *GIGYF1* pLOF also associated with decreased mean corpuscular hemoglobin levels and increased

- diagnosis of anemia as well as increased emphysema diagnosis. The biological basis for these
- associations is not clear. *GIGYF1* is highly expressed in lung [19, 30] although the emphysema
- association is driven by small numbers of individuals, so replication is required.
- 356 *GIGYF1* pLOF associated with a 4.5-fold increased risk of hypothyroidism and *GIGYF1* is highly expressed 357 in thyroid [19, 30] consistent with a biological function in this tissue. IGF-1 and insulin have been
- 358 implicated in the proliferation of thyroid cells which may, in part, explain the association with thyroid
- 359 dysfunction [34-36]. An alternative possibility is that GIGYF1 contributes to thyroid function by affecting
- 360 secretion of thyroid stimulating hormone in the anterior pituitary gland. Another explanation is that
- 361 shared autoimmune mechanisms contribute to thyroid dysfunction and diabetes in pLOF carriers and
- 362 that some of the carriers diagnosed with T2D have features of latent autoimmune diabetes in adults
- [37]. Damaging variants in *GIGYF1* have recently been implicated in conferring risk for developmental
- delay and autism spectrum disorders [38]. Consistent with this, we see an association of *GIGYF1* pLOF
- with increased time to complete a cognitive test. It may be that metabolic aberrations in carriers affect
- 366 cognitive performance, that brain development is altered due to perturbation of IGF-1 signaling, or that
- 367 other functions of GIGYF1 such as regulation of mRNA expression and decay are responsible for
- 368 cognitive phenotypes.
- 369 In addition to replicating the association of *GIGYF1* pLOF with T2D in an independent cohort we also
- used common genetic variants to further investigate the role of the *GIGYF1* locus in diabetes. Non-
- coding variants at the *GIGYF1* locus associated with glucose levels and T2D, and we replicated these
- findings in independent datasets. These variants associated with increased *GIGYF1* expression but a
- 373 lower risk of T2D. This direction of effect is consistent with what we see for the pLOF variants reduced
- 374 levels of *GIGYF1* increases diabetes risk but increased levels of *GIGYF1* are protective.
- We observed an intersection of rare and common variant associations at *GIGYF1* as well as at MODY genes such as *GCK*, *HNF1A* and *HNF4A*. However, in general, our gene-level analysis of rare variants did not identify many additional causal genes at GWAS loci; out of 558 variants associated with T2D [9] just
- 378 nine had rare variant associations at a nearby gene.
- We assessed the impact of pLOF and predicted damaging missense variants in approximately 17,000
- 380 genes on glycemic traits and uncovered a hitherto unappreciated role for *GIGYF1* in regulating blood
- sugar and protecting from T2D. By highlighting the importance of GIGYF1 and GRB adapter proteins in
- 382 modulating insulin signaling this finding may lead to new therapeutic approaches for the treatment of
- diabetes. Discoveries such as this are only possible by combining health-related data with the
- 384 sequencing of rare variants on a biobank scale.

385 Methods

386 The UK Biobank resource and data access

- The UK Biobank (UKBB) recruited ~500,000 participants in England, Wales, and Scotland between 2006
- and 2010 [39]. Written informed consent was obtained from all participants. Phenotypic data available
- includes age, sex, biomarker data and self-reported diseases collected at the time of baseline
- 390 assessment as well as disease diagnoses from inpatient hospital stays, the cancer registry and death
- 391 records obtained through the NHS. Approximately half of the participants also have diagnoses from
- primary care available. Array genotypes are available for nearly all participants and exome sequencing

data is available for 454,787 participants. The data used in this study were obtained from the UKBB
 through application 26041.

Population definition and PC calculation for subjects with exome data

- 396 Subject quality control was performed by Regeneron Genetics Center (RGC) and removed subjects with
- 397 evidence of contamination, unresolved duplications, sex discrepancies and discordance between exome
- 398 sequencing and genotyping data. Genetic relationships between participants were determined by RGC
- using the PRIMUS program [40]. For the unrelated subset all first- and second-degrees relatives and
- 400 some third-degree relatives were excluded.
- 401 Populations were defined through a combination of self-reported ethnicity and genetic principal
- 402 components. We selected the unrelated individuals who identify as White (Field 21000) and ran an
- 403 initial principal component analysis (PCA) on high quality common variants using eigenstrat [41]. SNPs
- 404 were filtered for missingness across individuals < 2%, MAF > 1%, regions of known long range LD [42],
- and pruned to independent markers with pairwise LD < 0.1. We then projected the principal
- 406 components (PCs) onto related individuals and removed all individuals +/- 3 standard deviations from
- 407 the mean of PCs 1-6. A final PC estimation was performed in eigenstrat [41] using unrelated subjects.
- 408 We then projected related individuals onto the PCs.

409 Exome sequencing and variant calling

- 410 DNA was extracted from whole blood and was sequenced by the RGC as described elsewhere [43].
- 411 Briefly, the xGen exome capture was used and reads were sequenced using the Illumina NovaSeq 6000
- 412 platform. Reads were aligned to the GRCh38 reference genome using BWA-mem [44]. Duplicate reads
- 413 were identified and excluded using the Picard MarkDuplicates tool (Broad Institute). Variant calling of
- 414 SNVs and indels was done using the WeCall variant caller (Genomics Plc.) to produce a GVCF for each
- subject. GVCFs were combined to using the GLnexus joint calling tool [45]. Post-variant calling filtering
- 416 was applied using the Goldilocks pipeline [43]. Variants were annotated using the Ensembl Variant Effect
- Predictor v95 [46] which includes a LOFTEE plug-in to identify high confidence (HC) pLOF variants [13].
- 418 Combined Annotation Dependent Depletion (CADD) scores were generated using the Whole Genome
- 419 Sequence Annotator (WGSA) AMI version 0.8.

420 Phenotype definitions

- 421 Blood biochemistry values were obtained for glucose (Field 30740) and HbA1c (Field 30750) from UKBB
- 422 and inverse rank normalized using the RNOmni R package [47], resulting in an approximately normal
- 423 distribution.
- 424 For disease diagnoses, ICD10 codes were obtained from inpatient hospital diagnoses (Field 41270),
- 425 causes of death (Field 40001 and 40002) and the cancer registry (Field 40006) from UKBB. Diagnoses
- 426 also included additional hospital episode statistics (HESIN) and death registry data made available by
- 427 UKBB in July 2020. T2D was defined as ICD10 E11. For the purposes of excluding diagnosed diabetics
- 428 from the glucose and HbA1c analysis we defined diabetes as ICD10 codes E10-E14 which includes both
- 429 T1D and T2D diagnoses.
- 430 For phenome-wide analyses, a selection of quantitative traits was obtained from other fields,
- 431 encompassing anthropometric measurements, blood counts, as well as blood and urine biochemistry.
- 432 Beyond these measurements, we selected additional quantitative traits found to be heritable (h²
- 433 significance flagged as at least "nominal" with a confidence level flagged as "medium" or "high") by the

- 434 Neale lab [25], using PHESANT to transform values to quantitative traits when necessary as they
- 435 describe. These included the results of cognitive tests. All quantitative traits were inverse rank
- 436 normalized using the RNOmni R package. [47]. For burden testing, we required at least 10 carriers to
- 437 have measurements. We also tested associations with ICD10-coded diagnoses (using 3 character codes)
- that had more than 500 cases in the White subset of participants with exome data and at least one
- 439 expected case carrier based on variant frequency and disease prevalence.
- Glucose and HbA1c values were also extracted from primary care data available for about half of the
- 441 cohort using the following read codes. Glucose: read 2 codes 44U..,44g..,
- 442 44g1.,44TJ.,44f..,44TK.,44f1.,44g0.,44f0. and read 3 codes XMOly, X772z, XE2mq; HbA1c: read 2 codes
- 443 42W5., 44TB., 66Ae0, 44TC., 42W4. and read 3 codes XaPbt, X772q, XaWP9, XaBLm, XaERp.
- Values were converted to IFCC units where necessary. Aberrantly high (\geq 45 mmol/L for glucose, \geq 300
- 445 mmol/mol for HbA1c) and extremely low values (≤ 0.6 mmol/L for glucose, ≤ 10 mmol/mol for HbA1c)
- 446 were excluded. The mean measurement per individual was then taken and inverse rank normalized prior
- to association testing. The mean age at measurement was also extracted and used as a covariate in the
- 448 regression.
- 449 Individuals taking cholesterol-lowering medication were identified using self-reported medications
- 450 recorded at their UKBB interview (Field 20003) and whether cholesterol-lowering medications were
- 451 recorded using the touchscreen questionnaire (Fields 6177 and 6153).

452 Gene-based association testing

- 453 For gene-based tests, autosomal rare pLOF variants were identified as follows; LOFTEE high confidence
- 454 LOFs, MAF \leq 1%, missingness across individuals \leq 2%, HWE p-value \geq 10⁻¹⁰. Predicted damaging missense
- 455 variants were defined as missense variants with a CADD PHRED-scaled score \geq 25, MAF \leq 1%,
- 456 missingness across individuals $\leq 2\%$, HWE p-value $\geq 10^{-10}$. Only genes with more than one pLOF variant
- 457 or damaging missense variant were tested.
- 458 Burden testing was performed unrelated White subset using glm in R, using a gaussian model for
- 459 quantitative traits and a binomial model for case-control analyses. Genotype was coded as 0 (no variant)
- 460 or 1 (any number of variants). We adjusted for age, sex and the first 12 PCs of genetic ancestry in the
- regression. Additionally, when testing for association with disease diagnoses, we included country of
- recruitment as a covariate as the time of available follow-up differs between England, Scotland and
- 463 Wales. Recruitment country was defined using the location of the relevant UKBB recruitment center
- 464 (Field 54). Associations were later confirmed using just participants recruited in England. For case-
- 465 control analyses we only ran tests where there was at least one expected case carrier based on variant
- frequency and disease prevalence. For quantitative traits we required at least 10 carriers to have
- 467 measurements.
- For glucose and HbA1c, to convert effect sizes from normalized values back to measured units, the
 estimates from the regression were multiplied by the standard deviation of these traits in the entire
 cohort.
- 471 SAIGE-Gene was run using the SAIGE R package (v0.36.5) [48] using settings recommend by the
- 472 developers and related individuals were included.
- 473 T2D drug targets were defined according to Flannick et al. [5].

474 Manhattan plots were created using the R Package CMplot (<u>https://github.com/YinLiLin/R-CMplot</u>).

475 Array association testing

- 476 Genotypes were obtained through array typing and imputation as described previously [49]. Population
- 477 definition and PC estimation for individuals with array data was performed as previously described [50].
- 478 We tested all variants with imputation quality score (info) \geq 0.8 and minor allele frequency (MAF) \geq 0.1%
- 479 in a 200Mb region around *GIGYF1* for association with glucose, HbA1c, T2D and hypothyroidism.
- 480 Association analyses were performed using an additive model in PLINK adjusting for age at recruitment
- 481 to UKBB, sex and the first 12 PCs of genetic ancestry. We also adjusted for country of recruitment where
- 482 appropriate. The most significant variant with info > 0.95 was selected as the lead variant at the locus.
- 483 We replicated the association of rs221783 with glucose using available summary statistics for Biobank
- 484 Japan for the trait "blood sugar" (<u>http://jenger.riken.jp/en/result</u>) [20]. We replicated the association of
- this variant with T2D diagnosis using summary statistics from FinnGen release 3 for the phenotype
- 486 "E4_DM2" (https://www.finngen.fi/en/access_results). The effect allele in these datasets was the
- 487 alternate allele "C". For consistency with the UKBB associations we have shown the effect for the "T"
- 488 allele.
- 489 Meta-analysis of the UKBB and replication dataset association results was performed with the METAL
- 490 software package using the classical method [51].
- 491 Region plots were created using LocusZoom [52]. LD calculations were performed in the White
- 492 population for array variants in a 500kb sliding window as follows; we extracted genotypes with info >
- 493 0.9, rounded them to whole numbers, mean-imputed missing genotypes and used the R "cor" function
- 494 to compute R which was then squared to get an R² value.

495 Gene expression and eQTL analysis

- 496 The expression of *GIGYF1* in various tissues was assessed using the GTEx portal (accessed 08/04/2020)
- 497 [19] and Human Protein Atlas (<u>http://www.proteinatlas.org</u>) [30]. eQTL data for rs221783 was obtained
- 498 from GTEx v8. For each tissue of interest, the best eQTL for *GIGYF1* was identified (GTEx v8 "eGene"). R²
- for rs221783 and the best *GIGYF1* eQTL was calculated as described above.

500 Replication analysis in GHS

- 501 The GHS MyCode Community Health Initiative study is a health system-based cohort and has been
- 502 described previously [53]. A subset of participants sequenced as part of the GHS-Regeneron Genetics
- 503 Center DiscovEHR partnership were included in this study. T2D status was defined based on meeting at
- least one of the following criteria: (1) clinical encounters due to or problem-lists diagnosis code for type
- 505 2 diabetes (ICD-10 code E11), or (2) HbA1c greater than 6.5%, or (3) use of diabetic oral hypoglycemic
- 506 medicine. Controls were participants who did not meet any of the criteria for case definition. Individuals
- 507 were excluded from the analysis if they had clinical encounters due to or problem-lists diagnosis code
- 508 for type 1 diabetes (ICD-10 code E10), or if they were treated with insulin but not with oral
- 509 hypoglycemic medicines.
- 510 Exome-sequencing, variant calling, quality control and gene-based tests were performed as previously
- 511 described [54]. Variant sets tested were pLOF variants (*GIGYF1* and *TNRC6B*) or pLOF plus missense
- variants predicted to be deleterious by 5/5 algorithms (*PFAS*) with MAF < 1%. The following variants
- 513 were classified as pLOF variants: frameshift-causing indels, variants affecting splice acceptor and donor

- sites, variants leading to stop gain, stop loss and start loss. The five missense deleterious algorithms
- used were SIFT [55], PolyPhen2 (HDIV), PolyPhen2 (HVAR) [56], LRT [57], and MutationTaster [58].
- Association testing was performed in the European ancestry population using the Firth logistic
- regression test implemented in REGENIE [59] as previously described [54].

518 Identification of potential causal genes at GWAS loci

- 519 For 558 variants identified as associating with T2D [9] we mapped the two closest protein coding genes
- using bedtools. This resulted in 1118 genes for which we had tested 2071 variant sets (pLOF and/or
- 521 damaging missense) in our primary analysis. Genes with $p < 2.41 \times 10^{-5}$ (correcting for 2071 variant sets
- 522 tested) for HbA1c or T2D were considered significant.

523 Ethics Statement

- 524 The UK Biobank resource is an approved Research Tissue Bank and is registered with the Human Tissue
- 525 Authority, which means that researchers who wish to use it do not need to seek separate ethics
- approval (unless re-contact with participants is required). Research in GHS was approved by the GHS
- 527 IRB, approval number 2006-0258. Written informed consent was obtained from all participants in UKBB
- 528 and GHS.

529 Data availability

- All phenotypic data and array genotypes used in this study are accessible through application to UKBB.
- 531 Currently, exome sequencing data for ~200,000 participants is available [38]; the remainder of the
- exome data used is scheduled for public release in 2021. Summary statistics for gene-level tests will be
- 533 made available upon publication.

534 Author Contributions

- A.D, L.W., M.P., A.F.C. and P.N. performed computational analyses; P.A., L.L. A.B. and RGC performed
- replication analysis in GHS; A.D. wrote the manuscript. All authors interpreted results and edited the
- 537 manuscript.

538 Competing Interests

- A.D, L.W., M.P., A.F.C., L.B., G.H. and P.N. are employees and stockholders of Alnylam Pharmaceuticals.
- 540 P.A., L.L. and A.B. are employees and stockholders of Regeneron Pharmaceuticals.

541 Acknowledgements

- 542 This research has been conducted using the UK Biobank Resource (Project 26041). We would like to
- thank the participants and researchers of UK Biobank for creating an open-access resource. We thank
- the UK Biobank Exome Sequencing Consortium and UK Biobank for facilitating exome sequencing of
- participants. We also thank the participants of the GHS MyCode initiative as well as participants and
- 546 investigators of the FinnGen study and Biobank Japan. We thank Mark McCarthy and Anna Gloyn for
- 547 comments on the manuscript. Data management and analytics were performed using the REVEAL/SciDB
- 548 translational analytics platform from Paradigm4.

549 **References**

550

King EA, Davis JW, Degner JF. Are drug targets with genetic support twice as likely to be
 approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability
 of drug approval. PLOS Genetics. 2019;15(12):e1008489. doi: 10.1371/journal.pgen.1008489.
 Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, et al. The support of human genetic

evidence for approved drug indications. Nature Genetics. 2015;47(8):856-60. doi: 10.1038/ng.3314.
Nguyen PA, Born DA, Deaton AM, Nioi P, Ward LD. Phenotypes associated with genes encoding
drug targets are predictive of clinical trial side effects. Nature Communications. 2019;10(1):1579. doi:
10.1038/s41467-019-09407-3.

Cirulli ET, White S, Read RW, Elhanan G, Metcalf WJ, Tanudjaja F, et al. Genome-wide rare
 variant analysis for thousands of phenotypes in over 70,000 exomes from two cohorts. Nat Commun.
 2020;11(1):542. Epub 2020/01/30. doi: 10.1038/s41467-020-14288-y. PubMed PMID: 31992710;
 PubMed Central PMCID: PMCPMC6987107.

5. Flannick J, Mercader JM, Fuchsberger C, Udler MS, Mahajan A, Wessel J, et al. Exome
sequencing of 20,791 cases of type 2 diabetes and 24,440 controls. Nature. 2019;570(7759):71-6. Epub
2019/05/24. doi: 10.1038/s41586-019-1231-2. PubMed PMID: 31118516; PubMed Central PMCID:
PMCPMC6699738.

5676.Moutsianas L, Agarwala V, Fuchsberger C, Flannick J, Rivas MA, Gaulton KJ, et al. The Power of568Gene-Based Rare Variant Methods to Detect Disease-Associated Variation and Test Hypotheses About569Complex Disease. PLOS Genetics. 2015;11(4):e1005165. doi: 10.1371/journal.pgen.1005165.

570 7. Bush WS, Oetjens MT, Crawford DC. Unravelling the human genome-phenome relationship
571 using phenome-wide association studies. Nat Rev Genet. 2016;17(3):129-45. Epub 2016/02/16. doi:
572 10.1038/nrg.2015.36. PubMed PMID: 26875678.

Diogo D, Tian C, Franklin CS, Alanne-Kinnunen M, March M, Spencer CCA, et al. Phenome-wide
 association studies across large population cohorts support drug target validation. Nat Commun.
 2018;9(1):4285. Epub 2018/10/18. doi: 10.1038/s41467-018-06540-3. PubMed PMID: 30327483;
 PubMed Central PMCID: PMCPMC6191429.

Vujkovic M, Keaton JM, Lynch JA, Miller DR, Zhou J, Tcheandjieu C, et al. Discovery of 318 new
 risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi ancestry meta-analysis. Nat Genet. 2020;52(7):680-91. Epub 2020/06/17. doi: 10.1038/s41588-020 0637-y. PubMed PMID: 32541925; PubMed Central PMCID: PMCPMC7343592.

10. Xue A, Wu Y, Zhu Z, Zhang F, Kemper KE, Zheng Z, et al. Genome-wide association analyses
identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes. Nature
Communications. 2018;9(1):2941. doi: 10.1038/s41467-018-04951-w.

Huang J, Ellinghaus D, Franke A, Howie B, Li Y. 1000 Genomes-based imputation identifies novel
and refined associations for the Wellcome Trust Case Control Consortium phase 1 Data. Eur J Hum
Genet. 2012;20(7):801-5. Epub 2012/02/02. doi: 10.1038/ejhg.2012.3. PubMed PMID: 22293688;
PubMed Central PMCID: PMCPMC3376268.

Scott RA, Scott LJ, Magi R, Marullo L, Gaulton KJ, Kaakinen M, et al. An Expanded Genome-Wide
Association Study of Type 2 Diabetes in Europeans. Diabetes. 2017;66(11):2888-902. Epub 2017/06/02.
doi: 10.2337/db16-1253. PubMed PMID: 28566273; PubMed Central PMCID: PMCPMC5652602.

591 13. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, et al. The mutational

592 constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434-43. Epub
593 2020/05/29. doi: 10.1038/s41586-020-2308-7. PubMed PMID: 32461654; PubMed Central PMCID:
594 PMCPMC7334197.

595 14. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-

onset diabetes of the young. N Engl J Med. 2001;345(13):971-80. Epub 2001/09/29. doi:

597 10.1056/NEJMra002168. PubMed PMID: 11575290.

Wessel J, Chu AY, Willems SM, Wang S, Yaghootkar H, Brody JA, et al. Low-frequency and rare
exome chip variants associate with fasting glucose and type 2 diabetes susceptibility. Nature
Communications. 2015;6(1):5897. doi: 10.1038/ncomms6897.

16. Zhou W, Zhao Z, Nielsen JB, Fritsche LG, LeFaive J, Gagliano Taliun SA, et al. Scalable generalized
linear mixed model for region-based association tests in large biobanks and cohorts. Nature Genetics.
2020;52(6):634-9. doi: 10.1038/s41588-020-0621-6.

Tikkanen E, Gustafsson S, Amar D, Shcherbina A, Waggott D, Ashley EA, et al. Biological Insights
Into Muscular Strength: Genetic Findings in the UK Biobank. Scientific Reports. 2018;8(1):6451. doi:
10.1038/s41598-018-24735-y.

Willems SM, Wright DJ, Day FR, Trajanoska K, Joshi PK, Morris JA, et al. Large-scale GWAS
identifies multiple loci for hand grip strength providing biological insights into muscular fitness. Nature
Communications. 2017;8(1):16015. doi: 10.1038/ncomms16015.

61019.Aguet F, Brown AA, Castel SE, Davis JR, He Y, Jo B, et al. Genetic effects on gene expression611across human tissues. Nature. 2017;550(7675):204-13. doi: 10.1038/nature24277.

612 20. Kanai M, Akiyama M, Takahashi A, Matoba N, Momozawa Y, Ikeda M, et al. Genetic analysis of 613 quantitative traits in the Japanese population links cell types to complex human diseases. Nat Genet.

2018;50(3):390-400. Epub 2018/02/07. doi: 10.1038/s41588-018-0047-6. PubMed PMID: 29403010.
 Saevarsdottir S, Olafsdottir TA, Ivarsdottir EV, Halldorsson GH, Gunnarsdottir K, Sigurdsson A, et

al. FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune thyroid disease. Nature.
 2020;584(7822):619-23. doi: 10.1038/s41586-020-2436-0.

618 22. Froguel P, Vaxillaire M, Sun F, Velho G, Zouali H, Butel MO, et al. Close linkage of glucokinase 619 locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature.

620 1992;356(6365):162-4. Epub 1992/03/12. doi: 10.1038/356162a0. PubMed PMID: 1545870.

621 23. Ellard S. Hepatocyte nuclear factor 1 alpha (HNF-1 alpha) mutations in maturity-onset diabetes 622 of the young. Hum Mutat. 2000;16(5):377-85. Epub 2000/11/03. doi: 10.1002/1098-

623 1004(200011)16:5<377::AID-HUMU1>3.0.CO;2-2. PubMed PMID: 11058894.

624 24. Stoffers DA, Ferrer J, Clarke WL, Habener JF. Early-onset type-II diabetes mellitus (MODY4)

625 linked to IPF1. Nat Genet. 1997;17(2):138-9. Epub 1997/11/05. doi: 10.1038/ng1097-138. PubMed 626 PMID: 9326926.

627 25. Churchhouse C. Details and Considerations of the UK Biobank GWAS. Neale lab.

628 2017; http://www.nealelab.is/blog/2017/9/11/details-and-considerations-of-theuk-biobank-gwas.

629 26. Holt LJ, Siddle K. Grb10 and Grb14: enigmatic regulators of insulin action--and more? Biochem J.

630 2005;388(Pt 2):393-406. Epub 2005/05/20. doi: 10.1042/BJ20050216. PubMed PMID: 15901248;
631 PubMed Central PMCID: PMCPMC1138946.

631 Publiced Central PMCID: PMCPMCI138946. 632 27. Giovannone B, Lee E, Laviola L, Giorgino F, Cleveland KA,

632 27. Giovannone B, Lee E, Laviola L, Giorgino F, Cleveland KA, Smith RJ. Two novel proteins that are 633 linked to insulin-like growth factor (IGF-I) receptors by the Grb10 adapter and modulate IGF-I signaling. J

634Biol Chem. 2003;278(34):31564-73. Epub 2003/05/29. doi: 10.1074/jbc.M211572200. PubMed PMID:63512771153.

63628.Prokopenko I, Poon W, Magi R, Prasad BR, Salehi SA, Almgren P, et al. A central role for GRB10 in637regulation of islet function in man. PLoS Genet. 2014;10(4):e1004235. Epub 2014/04/05. doi:

10.1371/journal.pgen.1004235. PubMed PMID: 24699409; PubMed Central PMCID: PMCPMC3974640.

639 29. Rampersaud E, Damcott CM, Fu M, Shen H, McArdle P, Shi X, et al. Identification of novel

640 candidate genes for type 2 diabetes from a genome-wide association scan in the Old Order Amish:

641 evidence for replication from diabetes-related quantitative traits and from independent populations.

642 Diabetes. 2007;56(12):3053-62. Epub 2007/09/12. doi: 10.2337/db07-0457. PubMed PMID: 17846126.

643 30. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics.

Tissue-based map of the human proteome. Science. 2015;347(6220):1260419. Epub 2015/01/24. doi:
 10.1126/science.1260419. PubMed PMID: 25613900.

646 31. Peter D, Weber R, Sandmeir F, Wohlbold L, Helms S, Bawankar P, et al. GIGYF1/2 proteins use 647 auxiliary sequences to selectively bind to 4EHP and repress target mRNA expression. Genes Dev.

648 2017;31(11):1147-61. Epub 2017/07/13. doi: 10.1101/gad.299420.117. PubMed PMID: 28698298;

649 PubMed Central PMCID: PMCPMC5538437.

Weber R, Chung MY, Keskeny C, Zinnall U, Landthaler M, Valkov E, et al. 4EHP and GIGYF1/2
Mediate Translation-Coupled Messenger RNA Decay. Cell Rep. 2020;33(2):108262. Epub 2020/10/15.
doi: 10.1016/j.celrep.2020.108262. PubMed PMID: 33053355.

Klimentidis YC, Arora A, Newell M, Zhou J, Ordovas JM, Renquist BJ, et al. Type-2 diabetes with
low LDL-C: genetic insights into a unique phenotype. bioRxiv. 2019;10.1101/837013 %J bioRxiv:837013.
doi: 10.1101/837013 %J bioRxiv.

- 65634.Clement S, Refetoff S, Robaye B, Dumont JE, Schurmans S. Low TSH requirement and goiter in657transgenic mice overexpressing IGF-I and IGF-Ir receptor in the thyroid gland. Endocrinology.
- 658 2001;142(12):5131-9. Epub 2001/11/20. doi: 10.1210/endo.142.12.8534. PubMed PMID: 11713206.
- 65935.Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP. Regulation of thyroid cell660proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev.

661 2001;22(5):631-56. Epub 2001/10/06. doi: 10.1210/edrv.22.5.0444. PubMed PMID: 11588145.

- 66236.Zaballos MA, Santisteban P. FOXO1 controls thyroid cell proliferation in response to TSH and663IGF-I and is involved in thyroid tumorigenesis. Mol Endocrinol. 2013;27(1):50-62. Epub 2012/11/20. doi:
- 64 10.1210/me.2012-1032. PubMed PMID: 23160481; PubMed Central PMCID: PMCPMC5416949.
- 665 37. Mishra R, Hodge KM, Cousminer DL, Leslie RD, Grant SFA. A Global Perspective of Latent 666 Autoimmune Diabetes in Adults. Trends Endocrinol Metab. 2018;29(9):638-50. Epub 2018/07/26. doi: 667 10.1016/j.tem.2018.07.001. PubMed PMID: 30041834.
- Satterstrom FK, Kosmicki JA, Wang J, Breen MS, De Rubeis S, An JY, et al. Large-Scale Exome
 Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of
 Autism. Cell. 2020;180(3):568-84 e23. Epub 2020/01/26. doi: 10.1016/j.cell.2019.12.036. PubMed PMID:
 31981491; PubMed Central PMCID: PMCPMC7250485.
- Allen N, Sudlow C, Downey D, Peakman T, Danesh J, Elliott P, et al. UK Biobank: current status
 and what it means for epidemiology. Health Policy Technol. 2012;1(3):123-6.
- 40. Staples J, Qiao D, Cho MH, Silverman EK, University of Washington Center for Mendelian G,
- Nickerson DA, et al. PRIMUS: rapid reconstruction of pedigrees from genome-wide estimates of identity
 by descent. Am J Hum Genet. 2014;95(5):553-64. Epub 2014/12/03. doi: 10.1016/j.ajhg.2014.10.005.
- 677 PubMed PMID: 25439724; PubMed Central PMCID: PMCPMC4225580.
- 41. Wang L, Zhang W, Li Q. AssocTests: An R Package for Genetic Association Studies. Journal of
 Statistical Software; Vol 1, Issue 5 (2020). 2020.
- 42. Price AL, Weale ME, Patterson N, Myers SR, Need AC, Shianna KV, et al. Long-range LD can
 confound genome scans in admixed populations. Am J Hum Genet. 2008;83(1):132-5; author reply 5-9.
- Epub 2008/07/09. doi: 10.1016/j.ajhg.2008.06.005. PubMed PMID: 18606306; PubMed Central PMCID:
 PMCPMC2443852.
- 43. Van Hout CV, Tachmazidou I, Backman JD, Hoffman JD, Liu D, Pandey AK, et al. Exome
- sequencing and characterization of 49,960 individuals in the UK Biobank. Nature. 2020;586(7831):74956. Epub 2020/10/23. doi: 10.1038/s41586-020-2853-0. PubMed PMID: 33087929.
- 687 44. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform.
- 688 Bioinformatics. 2009;25(14):1754-60. Epub 2009/05/20. doi: 10.1093/bioinformatics/btp324. PubMed 689 PMID: 19451168; PubMed Central PMCID: PMCPMC2705234.
- 69045.Lin MF, Rodeh O, Penn J, Bai X, Reid JG, Krasheninina O, et al. GLnexus: joint variant calling for691large cohort sequencing. bioRxiv. 2018:343970. doi: 10.1101/343970.

McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al. The Ensembl Variant Effect
Predictor. Genome Biol. 2016;17(1):122. Epub 2016/06/09. doi: 10.1186/s13059-016-0974-4. PubMed
PMID: 27268795; PubMed Central PMCID: PMCPMC4893825.

47. McCaw ZR, Lane JM, Saxena R, Redline S, Lin X. Operating Characteristics of the Rank-Based
Inverse Normal Transformation for Quantitative Trait Analysis in Genome-Wide Association Studies.
bioRxiv. 2019:635706. doi: 10.1101/635706.

69848.Zhou W, Nielsen JB, Fritsche LG, Dey R, Gabrielsen ME, Wolford BN, et al. Efficiently controlling699for case-control imbalance and sample relatedness in large-scale genetic association studies. Nat Genet.7002018;50(9):1335-41. Epub 2018/08/15. doi: 10.1038/s41588-018-0184-y. PubMed PMID: 30104761;

701 PubMed Central PMCID: PMCPMC6119127.

70249.Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. Genome-wide genetic data on703~500,000 UK Biobank participants. bioRxiv. 2017:166298. doi: 10.1101/166298.

50. Ward LD, Tu H-C, Quenneville C, Flynn-Carroll AO, Parker MM, Deaton AM, et al. Genome-wide
association study of circulating liver enzymes reveals an expanded role for manganese transporter
SLC30A10 in liver health. 2020;2020.05.19.104570. doi: 10.1101/2020.05.19.104570 %J bioRxiv.

707 51. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association
708 scans. Bioinformatics. 2010;26(17):2190-1. Epub 2010/07/10. doi: 10.1093/bioinformatics/btq340.
709 PubMed PMID: 20616382; PubMed Central PMCID: PMCPMC2922887.

- 710 52. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional
- visualization of genome-wide association scan results. Bioinformatics. 2010;26(18):2336-7. Epub
 2010/07/17. doi: 10.1093/bioinformatics/btq419. PubMed PMID: 20634204; PubMed Central PMCID:
 PMCPMC2935401.
- Dewey FE, Murray MF, Overton JD, Habegger L, Leader JB, Fetterolf SN, et al. Distribution and
 clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study.
- 716 Science. 2016;354(6319). Epub 2016/12/23. doi: 10.1126/science.aaf6814. PubMed PMID: 28008009.
- 717 54. Kosmicki JA, Horowitz JE, Banerjee N, Lanche R, Marcketta A, Maxwell E, et al. A catalog of
- associations between rare coding variants and COVID-19 outcomes. medRxiv. 2021. Epub 2021/03/04.
 doi: 10.1101/2020.10.28.20221804. PubMed PMID: 33655273; PubMed Central PMCID:
- 720 PMCPMC7924298.
- 721 55. Vaser R, Adusumalli S, Leng SN, Sikic M, Ng PC. SIFT missense predictions for genomes. Nat 722 Protoc. 2016;11(1):1-9. Epub 2015/12/04. doi: 10.1038/nprot.2015.123. PubMed PMID: 26633127.
- 723 56. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations
- using PolyPhen-2. Curr Protoc Hum Genet. 2013;Chapter 7:Unit7 20. Epub 2013/01/15. doi:
- 10.1002/0471142905.hg0720s76. PubMed PMID: 23315928; PubMed Central PMCID:
- 726 PMCPMC4480630.
- 57. Chun S, Fay JC. Identification of deleterious mutations within three human genomes. Genome
 Res. 2009;19(9):1553-61. Epub 2009/07/16. doi: 10.1101/gr.092619.109. PubMed PMID: 19602639;
 PubMed Central PMCID: PMCPMC2752137
- 729 PubMed Central PMCID: PMCPMC2752137.
- 58. Schwarz JM, Rodelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing
 potential of sequence alterations. Nat Methods. 2010;7(8):575-6. Epub 2010/08/03. doi:
- 732 10.1038/nmeth0810-575. PubMed PMID: 20676075.
- 733 59. Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, et al.
- 734 Computationally efficient whole genome regression for quantitative and binary traits.
- 735 2020:2020.06.19.162354. doi: 10.1101/2020.06.19.162354 %J bioRxiv.
- 736

737 Figures

738 Figure 1: Gene-level associations with glucose and HbA1c levels

- A) pLOF associations with glucose levels. B) Damaging missense variant (CADD score ≥ 25) associations
- 740 with glucose levels. C) pLOF associations with HbA1c. D) Damaging missense variant associations with
- 741 HbA1c levels. The red line indicates the threshold for significance, genes with significant associations are



746 Figure 2: Gene-level associations with T2D

A) pLOF associations with T2D diagnosis. B) Damaging missense variant (CADD score ≥ 25) associations

- 748 with T2D diagnosis. The red line indicates the threshold for significance, genes with significant
- 749 associations are labeled.
- 750



753 Figure 3: PheWAS of GIGYF1 pLOF

- 754 The x-axis is the beta (effect size in standard deviations) for the association and the y-axis is -log10(p-
- value). Quantitative traits are colored light blue and ICD10 diagnoses colored dark blue. Phenome-wide
- rticant associations are labeled. The dashed line indicates the p-value threshold for phenome-wide
- 757 significance. Protein; total protein, RH grip; right hand grip strength, round time: time to complete
- round (cognitive test), LH grip; left hand grip strength, PEF; peak expiratory flow.



Phewas of GIGYF1 pLOF



760

761 Figure 4: Locus plot of glucose associations at the *GIGYF1* locus

Association results for array genotyped and imputed variants are shown. The purple diamond represents

- the lead variant rs221783. Other variants are colored according to correlation (R²) with this marker
- 764 (legend at top-left). The region displayed is chr7: 100092914-100492914. Genomic coordinates are for
- 765 hg19.



766

767